{'fraction_non_alphanumeric': 0.015189873417721518, 'fraction_numerical': 0.002531645569620253, 'mean_word_length': 5.878260869565217, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Optimizing the pharmacology of acid control in acid-related disorders.

Clinical evidence supports the relationship between acid suppression and healing of duodenal ulceration and reflux esophagitis. In contrast to H2-receptor antagonists which suppress acid secretion by inhibiting the initial stimulation of the parietal cell, proton pump inhibitors directly inhibit hydrogen ion secretion and can, therefore, better provide the degree and duration of intragastric pH elevation necessary for the optimal management of duodenal ulceration and reflux esophagitis. Clinical studies have shown that proton pump inhibitors, such as omeprazole and lansoprazole, provide more rapid healing and higher healing rates for both duodenal ulcers and reflux esophagitis than do H2-receptor antagonists.